



RUSH UNIVERSITY MEDICAL CENTER

PGY2 Oncology Residency Program

Core Rotations	Preceptors
Hematology I (6 weeks) Hematology II (4 weeks) Stem Cell Transplant and Cellular Therapy (4 weeks)	<ul style="list-style-type: none"> ▪ Amanda Seddon, PharmD, BCPS, BCOP ▪ Becca Myers, PharmD, BCOP ▪ Brian Seyboth, PharmD, BCOP ▪ Danielle Murphy, PharmD ▪ Eris Tollkuci, PharmD, BCOP ▪ Justin Fisher, PharmD ▪ Niveen Hilal, PharmD
Investigational Drug Services (2 weeks)	<ul style="list-style-type: none"> ▪ Nanette Gamazon Masangcay, PharmD, BCPS ▪ Kristen Garcia, PharmD
Infusion Center Pharmacy (2 weeks)	<ul style="list-style-type: none"> ▪ Trevor Christ, PharmD, BCOP
Pediatric Hematology/Oncology (4 weeks)	<ul style="list-style-type: none"> ▪ Laura Gleason, PharmD, BCOP
Outpatient Hematology/Oncology Clinic (12 weeks)	<ul style="list-style-type: none"> ▪ Mildred Carino, PharmD, BCOP ▪ Trevor Christ, PharmD, BCOP ▪ Melika Fini, PharmD, BCOP
Elective Rotations (2-4 weeks)	Preceptors
Inpatient Medical Oncology Benign Hematology Outpatient Stem Cell Transplant Clinic Hematology III Stem Cell Transplant and Cellular Therapy II	<ul style="list-style-type: none"> ▪ Amanda Seddon, PharmD, BCPS, BCOP ▪ Becca Myers, PharmD, BCOP ▪ Brian Seyboth, PharmD, BCOP ▪ Danielle Murphy, PharmD ▪ Eris Tollkuci, PharmD, BCOP ▪ Justin Fisher, PharmD ▪ Niveen Hilal, PharmD
Oncology Informatics	<ul style="list-style-type: none"> ▪ Michael Yannell, PharmD, MBA, BCPS ▪ Matt Hoch, PharmD, MS, BCPS
Pharmacogenomics	<ul style="list-style-type: none"> ▪ Trevor Christ, PharmD, BCOP
Oral Chemotherapy Clinic	<ul style="list-style-type: none"> ▪ Megan Britton, PharmD, BCPS
Cardio-Oncology	<ul style="list-style-type: none"> ▪ Sally Arif, PharmD, BCPS, BCCP
Infectious Disease	<ul style="list-style-type: none"> ▪ Christy Varughese, PharmD, BCIDP ▪ Hayley Hodgson, PharmD, BCIDP
Pain and Palliative Care	<ul style="list-style-type: none"> ▪ Advanced Practice Provider
Longitudinal Experiences	
<p><i>Teaching Opportunities:</i></p> <ul style="list-style-type: none"> ▪ Precepting IPPE and APPE students ▪ Pharmacy Grand Rounds ▪ Patient case, journal club, and research presentations ▪ Pharmacy school didactic lecture, fellows lecture , nursing CE <p><i>Residency Research Project:</i></p> <ul style="list-style-type: none"> ▪ Present at HOPA Annual Conference 	<p><i>Policy/Management:</i></p> <ul style="list-style-type: none"> ▪ Chemotherapy subcommittee meeting participation ▪ Policy/Guideline development ▪ Medication Utilization Evaluation project <p><i>Pharmacy Services:</i></p> <ul style="list-style-type: none"> ▪ Practice Obligation: every fourth weekend ▪ In-house 24-hour On-Call Program

PGY2 Oncology Residency Program

The PGY2 Oncology Residency Program at Rush is a one year residency established to provide specialty training for residents interested in hematology, oncology and stem cell transplant. The PGY2 began in 2012 and currently the program has one PGY2 oncology resident. The program has received accreditation by the American Society of Health-System Pharmacists (ASHP).

PGY2 PURPOSE STATEMENT

The PGY2 Oncology Residency at Rush University Medical Center builds on the Doctor of Pharmacy education and PGY1 pharmacy residency program to contribute to the development of clinical pharmacists in acute and ambulatory care hematology, oncology and stem cell transplant. The program is designed to develop the resident's clinical expertise in the care of hematology/oncology patients through a variety of core and elective rotations. Additionally, residents will have opportunities to gain experience in teaching, research, oncology informatics and quality improvement. The primary goal of this program is to provide the resident with opportunities to function independently as a practitioner by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care. Residents who successfully complete our program are prepared for advanced patient care positions, along with board certification in oncology pharmacy.



Patient Care Experience: The resident will have the opportunity to participate in multidisciplinary care of hematology/oncology patients in an academic teaching environment. The resident will practice in a state-of-the-art, hematology/oncology facility which has a capacity of 64-beds, 32-beds which are designated for hematology/stem cell transplant.

The Rush University Cancer Center programs have received approval by the Commission on Cancer of the American College of Surgeons as an Academic Comprehensive Cancer Program. Our outpatient facility opened in January 2012 and has 56 infusion stations that treat approximately 80-100 patients per day. Opportunities for electives include, but are not limited to, gynecology/oncology, pain and palliative care and oncology informatics. Most rotations will be four weeks in length.

Research Experience: The PGY2 resident will be expected to complete a longitudinal research project in collaboration with an experienced preceptor. The project will be of the resident's choice and involve a hematology/oncology/stem cell transplant concept. The project will be presented at the Hematology/Oncology Pharmacy Association (HOPA) Conference in early spring. Time throughout the year will be dedicated for research activities.

Teaching Experience: The PGY2 resident will serve as a preceptor for Doctor of Pharmacy students enrolled at local colleges of pharmacy. There will be opportunities to participate in the didactic education at Midwestern University and Rosalind Franklin University as well as provide education to Rush's hematology/oncology fellows. The resident will also lead small group discussions with pharmacy students and PGY1 residents.

Staffing Experience: Service responsibilities include one out of every four weekends of clinical staffing.

On Call Program: The resident will be expected to take overnight call in the medical center one out of approximately every 14 nights. Responsibilities during call include, but are not limited to, pharmacokinetic drug monitoring, answering clinical questions, participation in code blue emergencies, approval of restricted antimicrobials, and participation in acute stroke emergencies.

For more information, visit our website: <https://www.rush.edu/health-care-professionals/career-opportunities/pharmacy-residencies> or contact the PGY2 Residency Program director and/or coordinators:

Amanda N. Seddon, PharmD, BCPS, BCOP
Director, PGY2 Oncology Residency Program
Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy
Rush University Medical Center
Assistant Professor of Pharmacy Practice, Midwestern University
312-9472406
Amanda.N.Seddon@rush.edu

Becca Myers, PharmD, BCOP
Project Coordinator, PGY2 Oncology Residency Program
Clinical Pharmacy Specialist
Hematology/Oncology/Cellular Therapy

Eris Tollkuci, PharmD, BCOP
Presentation Coordinator, PGY2 Oncology Residency Program
Clinical Assistant Professor
Hematology/Oncology/Cellular Therapy